These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 36851084)

  • 1. An Insight into Current Treatment Strategies, Their Limitations, and Ongoing Developments in Vaccine Technologies against Herpes Simplex Infections.
    Sharma D; Sharma S; Akojwar N; Dondulkar A; Yenorkar N; Pandita D; Prasad SK; Dhobi M
    Vaccines (Basel); 2023 Jan; 11(2):. PubMed ID: 36851084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Developments in Vaccination for Herpes Simplex Virus.
    Krishnan R; Stuart PM
    Front Microbiol; 2021; 12():798927. PubMed ID: 34950127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Herpes Simplex Vaccines: Prospects of Live-attenuated HSV Vaccines to Combat Genital and Ocular infections.
    Stanfield B; Kousoulas KG
    Curr Clin Microbiol Rep; 2015 Sep; 2(3):125-136. PubMed ID: 27114893
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Status of vaccine research and development of vaccines for herpes simplex virus.
    Johnston C; Gottlieb SL; Wald A
    Vaccine; 2016 Jun; 34(26):2948-2952. PubMed ID: 26973067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccines for Herpes Simplex: Recent Progress Driven by Viral and Adjuvant Immunology.
    Sandgren KJ; Truong NR; Smith JB; Bertram K; Cunningham AL
    Methods Mol Biol; 2020; 2060():31-56. PubMed ID: 31617171
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Herpes Simplex Virus 2 (HSV-2) gD Mutant Impaired for Neural Tropism Is Superior to an HSV-2 gD Subunit Vaccine To Protect Animals from Challenge with HSV-2.
    Wang K; Goodman KN; Li DY; Raffeld M; Chavez M; Cohen JI
    J Virol; 2016 Jan; 90(1):562-74. PubMed ID: 26559846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ocular herpes simplex: changing epidemiology, emerging disease patterns, and the potential of vaccine prevention and therapy.
    Pepose JS; Keadle TL; Morrison LA
    Am J Ophthalmol; 2006 Mar; 141(3):547-557. PubMed ID: 16490506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blocking herpes simplex virus 2 glycoprotein E immune evasion as an approach to enhance efficacy of a trivalent subunit antigen vaccine for genital herpes.
    Awasthi S; Huang J; Shaw C; Friedman HM
    J Virol; 2014 Aug; 88(15):8421-32. PubMed ID: 24829358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of gramicidin, a topical contraceptive and antimicrobial agent with anti-HIV activity, against herpes simplex viruses type 1 and 2 in vitro.
    Bourinbaiar AS; Coleman CF
    Arch Virol; 1997; 142(11):2225-35. PubMed ID: 9672588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lifetime quality-adjusted life years lost due to genital herpes acquired in the United States in 2018: a mathematical modeling study.
    You S; Yaesoubi R; Lee K; Li Y; Eppink ST; Hsu KK; Chesson HW; Gift TL; Berruti AA; Salomon JA; Rönn MM
    Lancet Reg Health Am; 2023 Mar; 19():100427. PubMed ID: 36950038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isolation of herpes simplex virus from sexually transmitted disease patients in Ibadan, Nigeria.
    Oni AA; Adu FD; Ekweozor CC
    Sex Transm Dis; 1994; 21(4):187-90. PubMed ID: 7974067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genital herpes simplex virus infections.
    Mertz GJ
    Med Clin North Am; 1990 Nov; 74(6):1433-54. PubMed ID: 2246948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Penciclovir cream--improved topical treatment for herpes simplex infections.
    Schmid-Wendtner MH; Korting HC
    Skin Pharmacol Physiol; 2004; 17(5):214-8. PubMed ID: 15452407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prophylactic Herpes Simplex Virus 2 (HSV-2) Vaccines Adjuvanted with Stable Emulsion and Toll-Like Receptor 9 Agonist Induce a Robust HSV-2-Specific Cell-Mediated Immune Response, Protect against Symptomatic Disease, and Reduce the Latent Viral Reservoir.
    Hensel MT; Marshall JD; Dorwart MR; Heeke DS; Rao E; Tummala P; Yu L; Cohen GH; Eisenberg RJ; Sloan DD
    J Virol; 2017 May; 91(9):. PubMed ID: 28228587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of the Herpes Simplex Virus 2 (HSV-2) Glycoprotein D/AS04 Vaccine against Genital HSV-2 and HSV-1 Infection and Disease in the Cotton Rat Sigmodon hispidus Model.
    Boukhvalova M; McKay J; Mbaye A; Sanford-Crane H; Blanco JC; Huber A; Herold BC
    J Virol; 2015 Oct; 89(19):9825-40. PubMed ID: 26178984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Herpes simplex virus type 2 trivalent protein vaccine containing glycoproteins C, D and E protects guinea pigs against HSV-1 genital infection.
    Egan K; Hook LM; Naughton A; Friedman HM; Awasthi S
    Hum Vaccin Immunother; 2020 Sep; 16(9):2109-2113. PubMed ID: 32347775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interventions for the prevention and treatment of herpes simplex virus in patients being treated for cancer.
    Glenny AM; Fernandez Mauleffinch LM; Pavitt S; Walsh T
    Cochrane Database Syst Rev; 2009 Jan; (1):CD006706. PubMed ID: 19160295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new promising candidate to overcome drug resistant herpes simplex virus infections.
    Zinser E; Krawczyk A; Mühl-Zürbes P; Aufderhorst U; Draßner C; Stich L; Zaja M; Strobl S; Steinkasserer A; Heilingloh CS
    Antiviral Res; 2018 Jan; 149():202-210. PubMed ID: 29155164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design of a multi-epitope protein vaccine against herpes simplex virus, human papillomavirus and Chlamydia trachomatis as the main causes of sexually transmitted diseases.
    Dorosti H; Eskandari S; Zarei M; Nezafat N; Ghasemi Y
    Infect Genet Evol; 2021 Dec; 96():105136. PubMed ID: 34775078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Associations of HLA-A, HLA-B and HLA-C alleles frequency with prevalence of herpes simplex virus infections and diseases across global populations: implication for the development of an universal CD8+ T-cell epitope-based vaccine.
    Samandary S; Kridane-Miledi H; Sandoval JS; Choudhury Z; Langa-Vives F; Spencer D; Chentoufi AA; Lemonnier FA; BenMohamed L
    Hum Immunol; 2014 Aug; 75(8):715-29. PubMed ID: 24798939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.